Phase II trial of weekly nab-paclitaxel with GM-CSF as an immune modulator in recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer: Clinical and immune responses.

被引：0
|
作者：
Ben Liao, John
Swensen, Ron E.
Reichow, Jessica
Ovenell, Kelsie J.
Childs, Jennifer
Higgins, Doreen
Buening, Barbara
Goff, Barbara Ann
Morishima, Chihiro
Disis, Mary L.
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Valley Medcl Ctr, Renton, WA USA
[3] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[4] Univ Washington, Medcl Ctr, Seattle, WA 98195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5580
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study
    Coleman, Robert L.
    Brady, William E.
    McMeekin, D. Scott
    Rose, Peter G.
    Soper, John T.
    Lentz, Samuel S.
    Hoffman, James S.
    Shahin, Mark S.
    GYNECOLOGIC ONCOLOGY, 2011, 122 (01) : 111 - 115
  • [22] Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
    Liao, John B.
    Gwin, William R.
    Urban, Renata R.
    Hitchcock-Bernhardt, Katie M.
    Coveler, Andrew L.
    Higgins, Doreen M.
    Childs, Jennifer S.
    Shakalia, Hania N.
    Swensen, Ron E.
    Stanton, Sasha E.
    Tinker, Anna, V
    Wahl, Tanya A.
    Ancheta, Richard G.
    McGonigle, Kathryn F.
    Dai, James Y.
    Disis, Mary L.
    Goff, Barbara A.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (09)
  • [23] A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study
    Monk, Bradley J.
    Kauderer, James T.
    Moxley, Katherine M.
    Bonebrake, Albert J.
    Dewdney, Summer B.
    Secord, Angeles Alvarez
    Ueland, Frederick R.
    Johnston, Carolyn M.
    Aghajanian, Carol
    GYNECOLOGIC ONCOLOGY, 2018, 151 (03) : 422 - 427
  • [24] Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer
    Olawaiye, Alexander B.
    Kim, Jae-Weon
    Bagameri, Andrea
    Bishop, Erin
    Chudecka-Glaz, Anita
    Devaux, Alix
    Gladieff, Laurence
    Gordinier, Mary E.
    Korach, Jacob
    McCollum, Michael E.
    Mileshkin, Linda
    Monk, Bradley J.
    Nicum, Shibani
    Nogueira-Rodrigues, Angelica
    Oaknin, Ana
    O'Malley, David M.
    Orlando, Mauro
    Dreiling, Lyndah
    Tudor, Julia C.
    Lorusso, Domenica
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (04)
  • [25] A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer
    McNeish, I. A.
    Ledermann, J. A.
    Webber, L.
    James, L.
    Kaye, S. B.
    Hall, M.
    Hall, G.
    Clamp, A.
    Earl, H.
    Banerjee, S.
    Kristeleit, R.
    Raja, F.
    Feeney, A.
    Lawrence, C.
    Dawson-Athey, L.
    Persic, M.
    Khan, I.
    ANNALS OF ONCOLOGY, 2014, 25 (10) : 1988 - 1995
  • [26] Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer
    Chelariu-Raicu, Anca
    Levenback, Charles
    Slomovitz, Brian
    Wolf, Judith
    Bodurka, Diane C.
    Kavanagh, John J.
    Morrison, Christopher
    Gershenson, David
    Coleman, Robert
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (11) : 1768 - 1774
  • [27] Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
    Fu, Siqing
    Corr, Bradley R.
    Culm-Merdek, Kerry
    Mockbee, Colleen
    Youssoufian, Hagop
    Stagg, Robert
    Naumann, R. Wendel
    Wenham, Robert M.
    Rosengarten, Rafael D.
    Benjamin, Laura
    Hamilton, Erika Paige
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (23) : 2568 - +
  • [28] Phase II trial of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Hagemann, Andrea R.
    Zighelboim, Israel
    Novetsky, Akiva Pesach
    Gao, Feng
    Massad, L. Stewart
    Thaker, Premal H.
    Powell, Matthew A.
    Mutch, David Gardner
    Wright, Jason D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer
    Liao, John B.
    Swensen, Ron E.
    Ovenell, Kelsie J.
    Hitchcock-Bernhardt, Katie M.
    Reichow, Jessica L.
    Apodaca, Minjun C.
    D'Amico, Leonard
    Childs, Jennifer S.
    Higgins, Doreen M.
    Buening, Barbara J.
    Goff, Barbara A.
    Disis, Mary L.
    GYNECOLOGIC ONCOLOGY, 2017, 144 (03) : 480 - 485
  • [30] Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer
    Anita Schwandt
    Vivian E. von Gruenigen
    Robert M. Wenham
    Heidi Frasure
    Susan Eaton
    Nancy Fusco
    Pingfu Fu
    John J. Wright
    Afshin Dowlati
    Steven Waggoner
    Investigational New Drugs, 2014, 32 : 729 - 738
12345